Michael J. Pencina
Affiliations: | Boston University, Boston, MA, United States |
Area:
Biostatistics Biology, StatisticsGoogle:
"Michael Pencina"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Khan SS, Coresh J, Pencina MJ, et al. (2023) Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation |
| Pencina MJ, Pencina KM, Lloyd-Jones D, et al. (2020) The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation. 142: 827-837 |
| Marquis-Gravel G, Roe MT, Robertson HR, et al. (2020) Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. Jama Cardiology |
| Brennan JM, Wruck L, Pencina MJ, et al. (2019) Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal. 218: 110-122 |
| Kent DM, van Klaveren D, Paulus JK, et al. (2019) The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. Annals of Internal Medicine |
| Chlebus K, Zdrojewski T, Gruchała M, et al. (2019) Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country. American Heart Journal. 218: 32-45 |
| Kohli-Lynch CN, Bellows BK, Thanassoulis G, et al. (2019) Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. Jama Cardiology |
| Edmonston D, Wojdyla D, Mehta R, et al. (2019) Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation |
| Pencina KM, Thanassoulis G, Wilkins JT, et al. (2019) Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. Journal of the American College of Cardiology. 74: 70-79 |
| Enserro DM, Demler OV, Pencina MJ, et al. (2019) Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. Statistics in Medicine |